Basic science reviews: Immunomodulation therapy for squamous cell carcinoma of the head and neck
- 1 May 1993
- journal article
- review article
- Published by Wiley in Head & Neck
- Vol. 15 (3) , 266-270
- https://doi.org/10.1002/hed.2880150318
Abstract
The role of the immune system in the pathogenesis and treatment of cancer is currently a popular area of research. An underlying fundamental concept of cancer immunology is the supposition that tumor cells express antigens differently than normal cells, both qualitatively and quantitatively. Understanding tumor–host interactions may suggest opportunities to modify these relationships to obtain antitumor effects. There is growing evidence that the immune system plays an important role in the pathogenesis of squamous cell carcinoma of the head and neck (SCCHN).1-4 Based on this evidence, trials studying the therapeutic efficacy of biologic response modifiers (BRMs) have been undertaken. These trials have had variable success, but continued efforts incorporating newer cytokines are underway.Keywords
This publication has 27 references indexed in Scilit:
- Interleukin-2, Cisplatin, and 5-Fluorouracil for Patients with Non-Small Cell Lung and Head/Neck CarcinomasJournal of Immunotherapy, 1991
- Interleukin‐2 injected around tumor‐draining lymph nodes in head and neck cancerHead & Neck, 1991
- Clinical and Immunopathological Results of a Phase II Study of Perilymphatically Injected Recombinant Interleukin-2 in Locally Far Advanced, Nonpretreated Head and Neck Squamous Cell CarcinomaJournal of Immunotherapy, 1991
- Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neckHead & Neck, 1991
- The Effect of Preoperative Local Interleukin-2 (IL-2) Injections in Patients with Head and Neck Squamous Cell Carcinoma: An Immunological StudyActa Oto-Laryngologica, 1991
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985